Related Experiment Videos
[Successful telithromycin therapy of Legionella pneumonia --report of three cases]
Akihiro Itoh1, Hiromi Tomioka, Masanori Isobe
1Department of Respiratory Medicine, Nishi-Kobe Medical Center.
Abstract:
Legionella species have been widely recognized as among the important causative organisms of community-acquired pneumonia in Japan. A delay in the start of adequate treatment has a negative influence on the outcome of the disease. Telithromycin, the first oral ketolide antibacterial, was developed for the treatment of community-acquired pneumonia, including Legionella pneumonia. However, few reports have indicated the efficacy of telithromycin in community-acquired pneumonia caused by Legionella species. We report three cases of Legionella pneumonia, that were improved by early telithromycin therapy. The first patient (67-year-old man) had bronchiectasis as an underlying disease, and the second patient (73-year-old man) had diabetes mellitus and chronic renal failure. The third patient (62-year-old man) developed pneumonia after a spa tour. The diagnosis of Legionella pneumonia was made on the basis of the presence of a single IgG titer of 1/256 in case 1 and positive antigenuria in cases 2 and 3. The patients were classified into a mild group (case 1) and a moderate group (cases 2 and 3) based on the severity of the community-acquired pneumonia according to the 2005 Japanese Respiratory Society Guidelines. The results support the efficacy of telithromycin in mild to moderate Legionella pneumonia.
Insights
Early telithromycin therapy shows promise for treating Legionella pneumonia, a common cause of community-acquired pneumonia. This study highlights its effectiveness in mild to moderate cases, improving patient outcomes.
Area of Science:
- Infectious Diseases
- Pulmonology
- Pharmacology
Background:
- Legionella species are significant causes of community-acquired pneumonia (CAP) in Japan.
- Prompt and effective treatment is crucial for favorable outcomes in Legionella pneumonia.
- Telithromycin, a ketolide antibiotic, was developed for CAP, but its efficacy against Legionella is not well-documented.
Observation:
- Three cases of Legionella pneumonia are presented, with patients experiencing improvement after early telithromycin administration.
- Case 1 involved a 67-year-old male with bronchiectasis; Cases 2 and 3 involved a 73-year-old male with diabetes and chronic renal failure, and a 62-year-old male who developed pneumonia post-spa tour, respectively.
- Diagnosis was confirmed via IgG titer (Case 1) and antigenuria (Cases 2 and 3).
Findings:
- Patients were categorized as mild (Case 1) or moderate (Cases 2 and 3) based on 2005 Japanese Respiratory Society Guidelines.
- All three patients demonstrated clinical improvement with early telithromycin therapy.
- The results suggest telithromycin is effective for mild to moderate Legionella pneumonia.
Implications:
- Early intervention with telithromycin may be a viable treatment option for Legionella pneumonia.
- This study contributes evidence supporting the use of telithromycin in specific CAP cases.
- Further research could explore broader applications and optimal dosing of telithromycin for Legionella infections.
Related Concept Videos
Atypical Pneumonia
Acute Pyelonephritis II: Diagnostic Studies and Management
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Rocky Mountain Spotted Fever
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories: